Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 287

1.

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.

Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V.

Oncology. 2007;73(3-4):221-7. doi: 10.1159/000127413. Epub 2008 Apr 17.

PMID:
18424886
2.

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV.

Ann Oncol. 2003 Jan;14(1):97-104.

3.

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.

J Clin Oncol. 2007 Oct 20;25(30):4787-92.

4.

[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].

Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.

Ai Zheng. 2007 Aug;26(8):890-4. Chinese.

PMID:
17697554
5.

Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.

Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH.

Asia Pac J Clin Oncol. 2011 Mar;7(1):82-7. doi: 10.1111/j.1743-7563.2010.01363.x. Epub 2010 Dec 22.

PMID:
21332655
6.

Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.

El-Hadaad HA, Wahba HA.

J Gastrointest Cancer. 2013 Sep;44(3):313-7. doi: 10.1007/s12029-013-9495-5.

PMID:
23606201
7.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
8.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
9.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

10.

Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.

Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T, Hatake K.

Breast Cancer. 2009;16(2):126-31. doi: 10.1007/s12282-008-0073-9. Epub 2008 Sep 20.

PMID:
18807123
11.

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.

Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.

Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7.

PMID:
18391598
12.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
13.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
14.

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.

Sakamoto J, Chin K, Kondo K, Kojima H, Terashima M, Yamamura Y, Tsujinaka T, Hyodo I, Koizumi W; Clinical Study Group of Capecitabine.

Anticancer Drugs. 2006 Feb;17(2):231-6.

PMID:
16428943
15.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.

Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F.

Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. Epub 2007 Dec 6.

PMID:
18071704
16.

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY.

Ann Oncol. 2004 Sep;15(9):1344-7.

17.
18.

Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.

Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H; JCOG Gastrointestinal Oncology Study Group.

Jpn J Clin Oncol. 2010 Jun;40(6):573-9. doi: 10.1093/jjco/hyq011. Epub 2010 Feb 25.

19.

Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.

Kindler HL, Aklilu M, Nattam S, Vokes EE.

Am J Clin Oncol. 2008 Dec;31(6):553-6. doi: 10.1097/COC.0b013e318178e4cd.

PMID:
19060586
20.

A pilot phase II study of capecitabine in advanced or recurrent breast cancer.

Saeki T, Kimura T, Toi M, Taguchi T.

Breast Cancer. 2006;13(1):49-57.

Items per page

Supplemental Content

Write to the Help Desk